Cannabics Pharmaceuticals Inc. Receives the Final Report of Its Research on Antitumor Properties of Cannabinoids Held in Israel

TEL AVIV, Israel, April 3, 2017, CNBX, /PRNewswire/ Cannabics Pharmaceuticals Inc. (CNBX) is pleased to announce that it received the final report of the research held in the Technion Israel Institute of Technology, in which the antitumor activity of cannabinoids was reflected in several types of cancer (breast, ovarian, colon, pancreatic, gastric, glioblastoma). The results which were obtained, using High Throughput Screening technology (HTS), clearly indicate that the company s cannabinoid compounds caused apoptosis (programed cancer cell death) in all
http://bit.ly/2nQprFK